1 / 96

Ärztlicher Direktor Dr. Ursula Jacob

Ärztlicher Direktor Dr. Ursula Jacob. Köln 2011. Therapiekonzepte in der Onkologie. ONCOTRACE. ONCOTRAIL. ONCOCOUNT. TU profile +. Case studies. Case report for hypertheramia treatment and sensitivity testing: Patient C.O., born 13.10.72

lavina
Download Presentation

Ärztlicher Direktor Dr. Ursula Jacob

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ärztlicher Direktor Dr. Ursula Jacob Köln 2011

  2. Therapiekonzepte in der Onkologie

  3. ONCOTRACE

  4. ONCOTRAIL

  5. ONCOCOUNT

  6. TU profile +

  7. Case studies

  8. Case report for hypertheramia treatment and sensitivity testing: • Patient C.O., born 13.10.72 • Diagnosis: 01/00 Hodgkin’s disease (nodular sclerotic). • Until 08/00 multiple chemotherapies and radiation with partial remission. • 10/00 recurrence right axilla. No therapy. • 02/01 progressive disease, chemotherapy with ESHAP. • Progressive disease. • 03/01 change of chemotherapy. • 06/01 progressive disease, high dosage chemotherapy, full remission. • 02/02 progressive disease lymph node right axillary region. Radiotherapy. • 08/03 progressive disease mediastinal, hilar lymph nodes, bilateral. CD30 antibody treatment, without effect. • 05/04 massive progressive disease in PET CT and clinically.Start of Gemzar mono without effect. High-dosed Prednisolone. • 08/04 in our treatment – chemosensitivity test showed Vinblastin in combination with Procarbazin in combination with CD20 antibody Mabthera until 12/04.Start of local chemotherapy plus systemic chemo, whole-body hyperthermia every few months until now.PET scan and MRI: full remission until now. • 12/08 microtumor testing showed cells under the norm. • 11/10 microtumor test: again cells under the normal limit. • Full remission

  9. ONCOTRACE 2007

  10. ONCOTRACE 2008

  11. ONCOTRACE 2010

  12. History Patient female D.F. dob.: 28.01.1947 • 2006: Abnormal mammogram then MRI diagnosed stage IV breast cancer with bone, liver and lymph node metastases. Therapy – bilateral mastectomy (ER+, HER2 –ve) then monthly Zometa, Femara • 2008: Hepatic recurrence, therapy changed from Femara to Xeloda plus Herceptin (now HER2 +) • 2009: Progressive disease. Xeloda increased. Tycarb commenced with initial beneficial effect but then further progression. Therapy changed to Abraxane plus Carboplatin (but reduced blood count) • 9/2010 Markedly progressive disease on CT with massive increase in hepatic tumour mass, therapy changed to Abraxane, Zometa and Herceptin with partial remission

  13. 29.9.10-4.11.10 Treatment in the clinic • Chemosensitivity test performed • Local therapy – chemoperfusion/chemoembolisation (Prof Vogl, Uniklinik Frankfurt), x3 (28.9.2010 Mitomycin C + Avastin, 12.10.2010 Mitomycin C + Avastin, 29.10.2010 Gemcitabine + Avastin) • Systemic chemotherapy – 2.10.2010 Navelbine 50 mg (together with whole body hyperthermia ) • Antibody therapy – Thalidomide • Anti-hormone therapy – Faslodex • Other therapies – Zometa, Bondronate • Supportive therapies – whole body hyperthermia (2.10.2010 [39.0], 8.10.2010 [39.1], 1.11.2011 [39.1]), photophoresis

  14. Given Medication • Oral – quercetin, Immune plus, vitamin D • Infusion – HepaMerz, vitamin C, selenium, Neurium, ProNeuroplus, Tationil • Parenteral – thymus/spleen extract, mesenchymal growth factors

  15. Ongoing therapy at home • Chemotherapy – Navelbine 50 mg 2-3 weekly (dependent on blood picture) • Antibody therapy – Thalidomide • Anti-hormone therapy – Faslodex 250 mg fortnightly • Oral – quercetin, vitamin D, Bondronate, Immune plus, Kwai (garlic extract), Chlorella, selenium, Hepamerz, CoQ10, probiotics, fish oil, B complex, Viromax • Parenteral – Lektinol, thymus, mesenchymal growth factors

  16. 25.1.2011-7.2.2011 Treatment in the clinic • Local therapy – chemoembolisation/chemoperfusion (Prof Vogl, Uniklinik Frankfurt) with Mitomycin C + Avastin (31.1.2011) • Systemic chemotherapy 27.1.2011 Navelbine 50 mg (together with whole body hyperthermia ) • Antibody therapy – Thalidomide (ceased 25.1.2011) replaced with Herceptin (3 weekly) • Anti-hormone therapy – Faslodex • Other therapies – Zometa, Bondronate • Supportive therapies – whole body hyperthermia (27.1.2011 [39.7], 3.2.2011 [39.0], photophoresis

  17. Given Medication • Oral – quercetin, Immune plus, vitamin D plus Vayara (Boswellia), CoQ10, melatonin, Bactoflor, • Infusion – HepaMerz, vitamin C, selenium, Neurium, ProNeuroplus, Tationil plus Artemesinin, Agaricus phalloides D4 • Parenteral – thymus/spleen extract, lektinol

  18. Ongoing therapy at home • Chemotherapy – Navelbine 50 mg 2-3 weekly (dependent on blood picture) • Antibody therapy – Herceptin 3 weekly • Anti-hormone therapy – Faslodex 250 mg fortnightly • Oral – vitamin D, Bondronate, Immune plus, selenium, Hepamerz, CoQ10, probiotics, fish oil, B complex plus Detoxolite, Agaricus phalloides D4, melatonin, Vayara (Boswellia), Aniflazyme, Nattokinase • Parenteral – Lektinol, thymus, mesenchymal growth factors

  19. 10.3.2011- 8.4.2011 Treatment in the clinic • Local therapy – chemoembolisation/chemoperfusion (Prof Vogl, Uniklinik Frankfurt) with Mitomycin C + Avastin (14.3.2011) • Antibody therapy – Removab 16.3.2011 (5 mcg), 21.3.2011 (10 mcg), 28.3.2011 (10 mcg) • Anti-hormone therapy – Faslodex • Other therapies – Zometa,

  20. Given Medication • Oral – Immune plus, vitamin D, Vayara (Boswellia), CoQ10, melatonin, Bactoflor, Detoxolite • Infusion – HepaMerz, vitamin C, selenium, Neurium, ProNeuroplus, Tationil plus Artemesinin, Agaricus phalloides D4 • Parenteral – thymus/spleen extract, lektinol, mesenchyme growth factors

  21. Staging – PET CT – 6.4.2011 total remission in bones and lungs, good partial remission in liver

  22. Ongoing therapy at home • Chemotherapy – Navelbine 50 mg 2-3 weekly (dependent on blood picture) • Antibody therapy – Herceptin 3 weekly • Anti-hormone therapy – Faslodex 250 mg fortnightly • Oral – vitamin D, Immune plus, Hepamerz, CoQ10, fish oil, B complex, Agaricus phalloides D4, Vayara (Boswellia), Aniflazyme, Nattokinase • Parenteral – Lektinol, mesenchymal growth factors

  23. 20.5.2011-28.5.2011 Treatment in the clinic • Local therapy – chemoembolisation/chemoperfusion (Prof Vogl, Uniklinik Frankfurt) with Mitomycin C + Avastin (19.5.2011) • Systemic chemotherapy 27.1.2011 Navelbine 50 mg (together with whole body hyperthermia ) • tumour specific targeted antibody therapy on 22.5.11 • Anti-hormone therapy – Faslodex • Other therapies – Zometa, Bondronate • Supportive therapies – whole body hyperthermia (23.5.2011), photophoresis

  24. Given Medication • Oral –Immune plus, vitamin D, Vayara (Boswellia), CoQ10, melatonin plus Biobran • Infusion – HepaMerz, vitamin C, selenium, Neurium, ProNeuroplus, Tationil, Artemesinin, Agaricus phalloides D4 • Parenteral – mesenchymal growth factors, lektinol

  25. Ongoing therapy at home • Chemotherapy – Navelbine 50 mg 2-3 weekly (dependent on blood picture) • Antibody therapy – Herceptin 3 weekly • Anti-hormone therapy – Faslodex 250 mg fortnightly • Oral – vitamin D, Bondronate, Immune plus, Hepamerz, CoQ10, fish oil, Agaricus phalloides D4, melatonin, Vayara (Boswellia), Aniflazyme, Nattokinase • Parenteral – Lektinol, mesenchymal growth factors

  26. 10.09.2011 – 06.10.2011 Treatment in the clinic • Local therapy – chemoembolisation/chemoperfusion (Prof Vogl, Uniklinik Frankfurt) with Mitomycin C + Avastin (13.9.2011) and 23.9.11 (with Gemcitabine) – initial MRI shows progressive hepatic disease • Antibody therapy – Removab (5 mcg 18.9.11, 10 mcg 28.9.11) • tumour specific targeted antibody therapy 7/11 and 09/11 • Anti-hormone therapy – Faslodex, changed to Tamoxifen 22.9.11 • Other therapies – Zometa, Bondronate, Pantozol • Supportive therapies – whole body hyperthermia (15.9.2011 [38,7], 26.9 [39,2]),

  27. Given Medication • Oral –Immune plus, vitamin D, Vayara (Boswellia), CoQ10, Nattokinase, Aniflazyme, Arcoxia (changed to Arthrotec), Membrain, glycine, Venalot, Cimetidine • Infusion – HepaMerz, vitamin C, selenium, Neurium, ProNeuroplus, Tationil, Artemesinin, Agaricus phalloides D4, DCA, zinc • Parenteral – thymus extract, lektinol, methylcobalamin, Iecur growth factors

  28. Staging PET CT (5.10.11) full remission

  29. ONCOTRACE

  30. History Patient female V.B. dob.: 18.12.1957 • 11/2010: Diagnosed with ovarian cancer with peritoneal carcinomatosis (Figo IIc). • Treated with debulking surgery and hysterectomy (with reduction in CA125) followed by 6 cycles of Taxol plus carboplatin with further reduction of tumour marker. • 1/2011 Chemosensitivity test performed

More Related